## Andrea Eva Steuer

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1908453/publications.pdf

Version: 2024-02-01

63 1,512 22 35 papers citations h-index g-index

65 65 65 1647 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Liquid Chromatography, in Combination with a Quadrupole Time-of-Flight Instrument (LC QTOF), with Sequential Window Acquisition of All Theoretical Fragment-Ion Spectra (SWATH) Acquisition: Systematic Studies on Its Use for Screenings in Clinical and Forensic Toxicology and Comparison with Information-Dependent Acquisition (IDA). Analytical Chemistry, 2014, 86, 11742-11749.	6.5	110
2	Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects. Clinical Pharmacokinetics, 2017, 56, 1219-1230.	3.5	96
3	Metabolomic Strategies in Biomarker Research–New Approach for Indirect Identification of Drug Consumption and Sample Manipulation in Clinical and Forensic Toxicology?. Frontiers in Chemistry, 2019, 7, 319.	3.6	82
4	From the Cover: Zebrafish Larvae Are Insensitive to Stimulation by Cocaine: Importance of Exposure Route and Toxicokinetics. Toxicological Sciences, 2016, 154, 183-193.	3.1	59
5	Single Hair Analysis of Small Molecules Using MALDI-Triple Quadrupole MS Imaging and LC-MS/MS: Investigations on Opportunities and Pitfalls. Analytical Chemistry, 2014, 86, 11758-11765.	6.5	58
6	Influence of Different Sewer Biofilms on Transformation Rates of Drugs. Environmental Science & Environmental	10.0	58
7	Time-dependent postmortem redistribution of butyrfentanyl and its metabolites in blood and alternative matrices in a case of butyrfentanyl intoxication. Forensic Science International, 2016, 266, 170-177.	2.2	55
8	Segmental hair analysis for differentiation of tilidine intake from external contamination using LCâ€ESlâ€MS/MS and MALDlâ€MS/MS imaging. Drug Testing and Analysis, 2015, 7, 143-149.	2.6	44
9	Studies on the metabolism of the fentanylâ€derived designer drug butyrfentanyl in human in vitro liver preparations and authentic human samples using liquid chromatographyâ€high resolution mass spectrometry (LCâ€HRMS). Drug Testing and Analysis, 2017, 9, 1085-1092.	2.6	44
10	Liquid Chromatography, In Combination with a Quadrupole Time-of-Flight Instrument, with Sequential Window Acquisition of All Theoretical Fragment-Ion Spectra Acquisition: Validated Quantification of 39 Antidepressants in Whole Blood As Part of a Simultaneous Screening and Quantification Procedure. Analytical Chemistry, 2015, 87, 9294-9301.	6.5	43
11	Systematic investigation of the incorporation mechanisms of zolpidem in fingernails. Drug Testing and Analysis, 2014, 6, 533-541.	2.6	41
12	Development and validation of a dynamic range-extended LC-MS/MS multi-analyte method for 11 different postmortem matrices for redistribution studies applying solvent calibration and additional 13C isotope monitoring. Analytical and Bioanalytical Chemistry, 2015, 407, 8681-8712.	3.7	40
13	Time-Dependent Postmortem Redistribution of Opioids in Blood and Alternative Matrices. Journal of Analytical Toxicology, 2018, 42, 365-374.	2.8	40
14	Comparison of conventional liquid chromatography–tandem mass spectrometry versus microflow liquid chromatography–tandem mass spectrometry within the framework of full method validation for simultaneous quantification of 40 antidepressants and neuroleptics in whole blood. Journal of Chromatography A, 2015, 1381, 87-100.	3.7	35
15	<i>In vitro</i> metabolism of the synthetic cannabinoids CUMYLâ€PINACA, 5F–CUMYLâ€PINACA, CUMYLâ€4CNâ€BINACA, 5F–CUMYLâ€P7AICA and CUMYLâ€4CNâ€B7AICA. Drug Testing and Analysis, 2018,	10 <del>7</del> .6	.57 <sup>35</sup>
16	Development and validation of an ultraâ€fast and sensitive microflow liquid chromatographyâ€tandem mass spectrometry (MFLCâ€MS/MS) method for quantification of LSD and its metabolites in plasma and application to a controlled LSD administration study in humans. Drug Testing and Analysis, 2017, 9, 788-797.	2.6	33
17	Time-dependent postmortem redistribution of morphine and its metabolites in blood and alternative matrices—application of CT-guided biopsy sampling. International Journal of Legal Medicine, 2017, 131, 379-389.	2.2	29
18	Identification of new urinary gammaâ€hydroxybutyric acid markers applying untargeted metabolomics analysis following placeboâ€controlled administration to humans. Drug Testing and Analysis, 2019, 11, 813-823.	2.6	29

#	Article	IF	CITATIONS
19	Hair Analysis: Contamination versus Incorporation from the Circulatory System—Investigations on Single Hair Samples Using Time-of-Flight Secondary Ion Mass Spectrometry and Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry. Analytical Chemistry, 2019, 91, 4132-4139.	6.5	28
20	Evaluation of drug incorporation into hair segments and nails by enantiomeric analysis following controlled single MDMA intakes. Analytical and Bioanalytical Chemistry, 2016, 408, 545-556.	3.7	27
21	Method development and validation for simultaneous quantification of 15 drugs of abuse and prescription drugs and 7 of their metabolites in whole blood relevant in the context of driving under the influence of drugs––Usefulness of multi-analyte calibration. Forensic Science International, 2014, 244. 92-101.	2.2	23
22	Development of CT-guided biopsy sampling for time-dependent postmortem redistribution investigations in blood and alternative matricesâ€"proof of concept and application on two cases. Analytical and Bioanalytical Chemistry, 2016, 408, 1249-1258.	3.7	22
23	A new metabolomics-based strategy for identification of endogenous markers of urine adulteration attempts exemplified for potassium nitrite. Analytical and Bioanalytical Chemistry, 2017, 409, 6235-6244.	3.7	22
24	(Un)targeted hair metabolomics: first considerations and systematic evaluation on the impact of sample preparation. Analytical and Bioanalytical Chemistry, 2019, 411, 3963-3977.	3.7	21
25	Analytical considerations for (un)â€targeted metabolomic studies with special focus on forensic applications. Drug Testing and Analysis, 2019, 11, 678-696.	2.6	21
26	Chiral Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine and its Phase I and II Metabolites following Controlled Administration to Humans. Drug Metabolism and Disposition, 2015, 43, 1864-1871.	3.3	20
27	Human Metabolome Changes after a Single Dose of 3,4-Methylenedioxymethamphetamine (MDMA) with Special Focus on Steroid Metabolism and Inflammation Processes. Journal of Proteome Research, 2018, 17, 2900-2907.	3.7	19
28	Comparative Untargeted Metabolomics Analysis of the Psychostimulants 3,4-Methylenedioxy-Methamphetamine (MDMA), Amphetamine, and the Novel Psychoactive Substance Mephedrone after Controlled Drug Administration to Humans. Metabolites, 2020, 10, 306.	2.9	19
29	Fatal poisoning involving cyclopropylfentanyl — Investigation of time-dependent postmortem redistribution. Forensic Science International, 2019, 294, 80-85.	2.2	17
30	Cheating on forensic hair testing? Detection of potential biomarkers for cosmetically altered hair samples using untargeted hair metabolomics. Analyst, The, 2020, 145, 6586-6599.	3.5	17
31	Purple discoloration of the colon found during autopsy: Identification of betanin, its aglycone and metabolites by liquid chromatography–high-resolution mass spectrometry. Forensic Science International, 2014, 240, e1-e6.	2.2	16
32	Postmortem distribution and redistribution of MDAI and 2-MAPB in blood and alternative matrices. Forensic Science International, 2017, 279, 83-87.	2.2	16
33	Blood alcohol analysis alone versus comprehensive toxicological analysis $\hat{a} \in \text{``Systematic'}$ investigation of missed co-ingested other drugs in suspected alcohol-impaired drivers. Forensic Science International, 2016, 267, 52-59.	2.2	15
34	First Time View on Human Metabolome Changes after a Single Intake of 3,4-Methylenedioxymethamphetamine in Healthy Placebo-Controlled Subjects. Journal of Proteome Research, 2017, 16, 3310-3320.	3.7	15
35	Chiral analysis of amphetamines in hair by liquid chromatography–tandem mass spectrometry: complianceâ€monitoring of attention deficit hyperactivity disorder (ADHD) patients under Elvanse® therapy and identification after controlled lowâ€dose application. Drug Testing and Analysis, 2018, 10, 254-261.	2.6	14
36	MALDI-MS drug analysis in biological samples: opportunities and challenges. Bioanalysis, 2016, 8, 1859-1878.	1.5	13

#	Article	IF	Citations
37	Antemortem and postmortem influences on drug concentrations and metabolite patterns in postmortem specimens. Wiley Interdisciplinary Reviews Forensic Science, 2019, 1, .	2.1	13
38	Towards Extending the Detection Window of Gamma-Hydroxybutyric Acid—An Untargeted Metabolomics Study in Serum and Urine Following Controlled Administration in Healthy Men. Metabolites, 2021, 11, 166.	2.9	13
39	Retrospective monitoring of long-term recreational and dependent cocaine use in toenail clippings/scrapings as an alternative to hair. Bioanalysis, 2014, 6, 3183-3196.	1.5	12
40	A possible new oxidation marker for hair adulteration: Detection of PTeCA (1Hâ€pyrroleâ€2,3,4,5â€tetracarboxylic acid) in bleached hair. Drug Testing and Analysis, 2020, 12, 230-238.	2.6	12
41	Towards Best Practice in Hair Metabolomic Studies: Systematic Investigation on the Impact of Hair Length and Color. Metabolites, 2020, 10, 381.	2.9	12
42	Development and validation of an LCâ€MS/MS method after chiral derivatization for the simultaneous stereoselective determination of methylenedioxyâ€methamphetamine (MDMA) and its phase I and II metabolites in human blood plasma. Drug Testing and Analysis, 2015, 7, 592-602.	2.6	11
43	Inhibition potential of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites on the in vitro monoamine oxidase (MAO)-catalyzed deamination of the neurotransmitters serotonin and dopamine. Toxicology Letters, 2016, 243, 48-55.	0.8	11
44	Development of a highâ€speed MALDIâ€triple quadrupole mass spectrometric method for the determination of 3,4â€methylenedioxymethamphetamine (MDMA) in oral fluid. Drug Testing and Analysis, 2016, 8, 235-240.	2.6	10
45	Parameter Optimization for Feature and Hit Generation in a General Unknown Screening Method—Proof of Concept Study Using a Design of Experiment Approach for a High Resolution Mass Spectrometry Procedure after Data Independent Acquisition. Analytical Chemistry, 2018, 90, 3531-3536.	6.5	10
46	Suitability evaluation of new endogenous biomarkers for the identification of nitriteâ€based urine adulteration in mass spectrometry methods. Drug Testing and Analysis, 2019, 11, 230-239.	2.6	10
47	Time- and Site-Dependent Postmortem Redistribution of Antidepressants and Neuroleptics in Blood and Alternative Matrices. Journal of Analytical Toxicology, 2021, 45, 356-367.	2.8	10
48	Aldosterone deficiency in mice burdens respiration and accentuates diet-induced hyperinsulinemia and obesity. JCI Insight, 2018, 3, .	5.0	10
49	Identification of urinary metabolites of the synthetic cannabinoid 5F-CUMYL-P7AICA in human casework. Forensic Science International, 2019, 294, 76-79.	2.2	9
50	Postmortem Metabolomics: Strategies to Assess Time-Dependent Postmortem Changes of Diazepam, Nordiazepam, Morphine, Codeine, Mirtazapine and Citalopram. Metabolites, 2021, 11, 643.	2.9	9
51	Untargeted metabolomics approaches to improve casework in clinical and forensic toxicology—"Where are we standing and where are we heading?― Wiley Interdisciplinary Reviews Forensic Science, 2022, 4, e1449.	2.1	9
52	Assessment of simpler calibration models in the development and validation of a fast postmortem multi-analyte LC-QTOF quantitation method in whole blood with simultaneous screening capabilities using SWATH acquisition. Analytical and Bioanalytical Chemistry, 2017, 409, 6495-6508.	3.7	8
53	Evaluation of endogenous urinary biomarkers for indirect detection of urine adulteration attempts by five different chemical adulterants in mass spectrometry methods. Drug Testing and Analysis, 2019, 11, 638-648.	2.6	8
54	Interpretable machine learning model to detect chemically adulterated urine samples analyzed by high resolution mass spectrometry. Clinical Chemistry and Laboratory Medicine, 2021, 59, 1392-1399.	2.3	8

#	Article	IF	CITATIONS
55	Impact of Cytochrome P450 2D6 Function on the Chiral Blood Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine (MDMA) and Its Phase I and II Metabolites in Humans. PLoS ONE, 2016, 11, e0150955.	2.5	7
56	Analytical considerations for postmortem metabolomics using GC-high-resolution MS. Analytical and Bioanalytical Chemistry, 2020, 412, 6241-6255.	3.7	7
57	Cyanide detection in gastric juice with corrin-based chemosensors. Analytical Methods, 2015, 7, 9707-9712.	2.7	6
58	Postmortem computed tomography and magnetic resonance imaging facilitates forensic autopsy in a fatal case of poisoning with formic acid, diphenhydramine, and ethanol. Forensic Science, Medicine, and Pathology, 2016, 12, 304-311.	1.4	6
59	In situ postmortem ethanol quantification in the cerebrospinal fluid by nonâ€waterâ€suppressed proton MRS. NMR in Biomedicine, 2019, 32, e4081.	2.8	6
60	Postmortem metabolomics: Correlating timeâ€dependent concentration changes of xenobiotic and endogenous compounds. Drug Testing and Analysis, 2020, 12, 1171-1182.	2.6	6
61	Towards a New Qualitative Screening Assay for Synthetic Cannabinoids Using Metabolomics and Machine Learning. Clinical Chemistry, 2022, 68, 848-855.	3.2	6
62	Significance of Metabolite Ratios in the Interpretation of Segmental Hair Testing Resultsâ€"Differentiation of Single from Chronic Morphine Use in a Case Series. Metabolites, 2021, 11, 557.	2.9	3
63	Easy and convenient millimoleâ€scale synthesis of new, potential biomarkers for gammaâ€hydroxybutyric acid (GHB) intake: Feasible for analytical laboratories. Drug Testing and Analysis, 2022, , .	2.6	3